bioMérieux, a world leader in the field of in vitro diagnostics, has received U.S. Food and Drug Administration (FDA) Clinical Laboratory Improvement Amendments (CLIA) waiver for the fast and accurate multiplex PCR*-based BIOFIRE® SPOTFIRE® Respiratory (R) Panel Mini. This waiver comes in addition to the 510(k) clearance obtained last April.
Swipe to discover more
bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the three months ended March 31th, 2023. Consolidated sales totaled €906 million in the first quarter of 2023, up 8.2% from €837 million in the year‑earlier period.
The Global Point Prevalence Survey (Global-PPS) is a free, online tool, developed by the University of Antwerp in Belgium, to measure and monitor antimicrobial prescribing and resistance in hospitals worldwide. Since its creation and launched in 2015, more than 90 countries have taken part in the initiative, involving 1,300 hospitals and 500,000 patients.
bioMérieux and JMI Laboratories (JMI) are announcing a six-year partnership to undertake collaborative projects evaluating the performance and increasing potential of rapid and innovative microbiology diagnostics as important tools in the battle against AMR.
?qlt=85&ts=1670238196189&dpr=off)
